Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor α but not methotrexate

Arthritis and Rheumatism

Volumn 60, Issue 10, 2009, Pages 2880-2891

  Varani, Katia ^a   Massara, Alfonso ^a   Vincenzi, Fabrizio ^a   Tosi, Alice ^a   Padovan, Melissa ^a   Trotta, Francesco ^a   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE RECEPTOR; CYCLIC AMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; METHOTREXATE; PROTEIN P50; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; WESTERN BLOTTING; CASE CONTROL STUDY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CYCLIC AMP; FEMALE; GTP-BINDING PROTEINS; HUMANS; LYMPHOCYTES; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPHILS; NF-KAPPA B; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A3; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 70349773147     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24794     Document Type: Article

References (50)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361
2. Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Mikuls TR, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35: 1015-1022 (Pubitemid 351813146)
3. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094-1099
4. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-172 (Pubitemid 41043882)
5. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007;11:1369-1384 (Pubitemid 350200476)
6. Caporali R, Pallavicini FB, Filippini M, Gorla R, Marchesoni A, Favalli EG, et al. Treatment of rheumatoid arthritis with anti-TNFα agents: a reappraisal. Autoimmun Rev 2009;8:274-280
7. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Study Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54: 26-37.
8. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-1074
9. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443
10. Akkari R, Burbiel JC, Hockemeyer J, Muller CE. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem 2006;6:1375-1399 (Pubitemid 44144923)
11. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nature Rev Drug Discov 2006;5:247-264
12. Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007;12:479-492
13. 3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008;117:123-140
14. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 2007;64:1471-1483
15. Fredholm BB. Adenosine receptors as targets for drug development. Drug News Perspect 2003;16:283-289 (Pubitemid 37176216)
16. Borea PA, Varani K, Dalpiaz A, Capuzzo A, Fabbri E, Ijzerman AP. Full and partial agonistic behaviour and thermodynamic binding parameters of adenosine A1 receptor ligands. Eur J Pharmacol 1994;267:55-61. (Pubitemid 24093347)
17. 2A receptors of human circulating blood elements. Drug Dev Res 1998;45:253-260
18. 2A adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J 2003;17:280-282
19. 2B receptors. Biochem Pharmacol 2005;70:1601-1612
20. Morovic-Vergles J, Culo MI, Gamulin S, Culo F. Cyclic adenosine 5′-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheumatol Int 2008;29:167-171
21. Baraldi PG, Tabrizi MA, Gessi S, Borea PA. Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem Rev 2008;108:238-263 (Pubitemid 351176408)
22. 2A adenosine receptor expression by TNF-α in PBMC of patients with CHF: a regulatory mechanism of inflammation. J Card Fail 2005;11:67-73.
23. 2A receptor inhibits LPS-induced expression of intercellular adhesion molecule 1 and production of TNF-α in human peripheral blood mononuclear cells. Shock 2008;29:154-159
24. Takahashi HK, Iwagaki H, Hamano R, Wake H, Kanbe T, Liu K, et al. Effects of adenosine on adhesion molecule expression and cytokine production in human PBMC depend on the receptor subtype activated. Br J Pharmacol 2007;150:816-822 (Pubitemid 46440211)
25. Forrest CM, Harman G, McMillan RB, Stoy N, Stone TW, Darlington LG. Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:89-92. (Pubitemid 40424764)
26. Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman A, Shanley TP, et al. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-387 (Pubitemid 28425204)
27. 3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-247
28. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:656-663 (Pubitemid 30394958)
29. 3 adenosine receptor expression. Arthritis Res Ther 2006;8:R169.
30. Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008;58: 3675-3683
31. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, DaSilva J, et al. A selective small molecule IκB kinase β inhibitor blocks nuclear factor κB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes and mast cells. J Pharmacol Exp Ther 2006;317:989-1001. (Pubitemid 43764101)
32. 3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-κB in mediating receptor level. J Rheumatol 2007;34:20-26
33. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, et al. The PI3K-NF-κB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 2006;8:R33.
34. Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007;16:1601-1613 (Pubitemid 47261623)
35. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 2008;35:41-48
36. Erer B, Yilmaz G, Yilmaz FM, Koklu S. Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-α therapy. Rheumatol Int 2009;29:651-654
37. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
38. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 1976;72:248-254
39. 3 adenosine receptors. Mol Pharmacol 2000;57:968-975
40. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, et al. Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol 2002;119:923-933 (Pubitemid 35340920)
41. Pearson T, Nuritova F, Caldwell D, Dale N, Frenguelli BG. A depletable pool of adenosine area CA1 of the rat hippocampus. J Neurosci 2001;21:2298-2307 (Pubitemid 32240528)
42. Gomez Cabrera MC, Martinez A, Santangelo G, Pallardo FV, Sastre J, Vina J. Oxidative stress in marathon runners: interest of antioxidant supplementation. Br J Nutr 2006;96 Suppl 1:S31-3.
43. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for the characterization of ligand-binding systems. Anal Biochem 1980;107:220-239
44. Wall M, Atterbury A, Dale N. Control of basal extracellular adenosine concentration in rat cerebellum. J Physiol 2007;582: 137-151 (Pubitemid 46993567)
45. Bekar L, Libionka W, Tian GF, Xu Q, Torres A, Wang X, et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. Nat Med 2008;14:75-80.
46. Klaasse EC, Ijzerman AP, de Grip WJ, Beukers MW. Internalization and desensitization of adenosine receptors. Purinergic Signal 2008;4:21-37.
47. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published erratum appears in N Engl J Med 2001;344:240 and N Engl J Med 2001;344:76]. N Engl J Med 2000;343:1586-1593
48. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-784
49. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47:584-590 (Pubitemid 351619194)
50. Dichamp I, Bourgeois A, Dirand C, Herbein G, Wendling D. Increased nuclear factor-κB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-α. J Rheumatol 2007;4:1976-1983 (Pubitemid 47548197)